Free Trial

Surgery Partners (SGRY) Financials

Surgery Partners logo
$22.80 -0.09 (-0.39%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$23.02 +0.22 (+0.96%)
As of 05/29/2025 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Surgery Partners

Annual Income Statements for Surgery Partners

This table shows Surgery Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
-168 -12 -55 -81 -156 -111 -238 9.45 1.43
Consolidated Net Income / (Loss)
13 135 87 71 1.30 45 -96 85 73
Net Income / (Loss) Continuing Operations
13 135 87 71 1.30 45 -96 85 73
Total Pre-Tax Income
147 135 110 81 -19 55 -69 92 -76
Total Operating Income
349 328 345 302 183 236 78 196 145
Total Gross Profit
1,192 1,950 1,083 944 771 774 497 324 291
Total Revenue
3,114 2,743 2,539 2,225 1,860 1,831 1,772 1,145 960
Operating Revenue
3,114 2,743 2,539 2,225 1,860 1,831 1,772 1,145 960
Total Cost of Revenue
1,922 794 1,456 1,281 1,089 1,058 1,275 821 669
Operating Cost of Revenue
1,922 794 1,456 1,281 1,089 1,058 1,275 821 669
Total Operating Expenses
843 1,622 738 642 588 538 419 128 146
Selling, General & Admin Expense
496 1,338 528 466 401 353 94 60 56
Depreciation Expense
153 118 115 99 95 77 67 40 35
Other Operating Expenses / (Income)
116 101 96 53 36 83 110 34 40
Restructuring Charge
100 62 48 40 23 19 32 8.74 18
Other Special Charges / (Income)
-21 3.10 -48 -16 -0.50 -1.20 42 -14 -2.62
Total Other Income / (Expense), net
-202 -193 -235 -221 -202 -181 -147 -104 -221
Interest & Investment Income
-202 -193 -235 -221 -202 -179 -147 -101 -101
Income Tax Expense
135 -0.30 23 11 -20 9.50 26 7.10 -149
Net Income / (Loss) Attributable to Noncontrolling Interest
181 147 142 142 157 156 143 76 71
Basic Earnings per Share
($1.33) ($0.09) ($0.59) ($1.12) ($3.19) ($2.29) ($4.96) $0.20 $0.04
Weighted Average Basic Shares Outstanding
126.12M 125.61M 91.95M 72.43M 48.78M 48.28M 48.03M 48.02M 36.07M
Diluted Earnings per Share
($1.33) ($0.09) ($0.59) ($1.12) ($3.19) ($2.29) ($4.96) $0.20 $0.04
Weighted Average Diluted Shares Outstanding
126.12M 125.61M 91.95M 72.43M 48.78M 48.28M 48.03M 48.19M 37.46M
Weighted Average Basic & Diluted Shares Outstanding
127.61M 126.61M 126.03M 89.36M 48.78M 48.28M 48.03M 48.63M 35.70M

Quarterly Income Statements for Surgery Partners

This table shows Surgery Partners' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-109 -32 -16 -12 -1.00 -4.90 19 -25 -23 -25
Consolidated Net Income / (Loss)
-47 6.40 28 24 47 30 58 1.20 23 5.60
Net Income / (Loss) Continuing Operations
-47 6.40 28 24 47 30 58 1.20 23 5.60
Total Pre-Tax Income
74 11 33 29 53 33 50 -0.40 33 13
Total Operating Income
127 61 85 76 101 83 98 46 94 74
Total Gross Profit
97 542 294 259 768 479 472 230 395 221
Total Revenue
864 770 762 717 735 674 668 666 707 621
Operating Revenue
864 770 762 717 735 674 668 666 707 621
Total Cost of Revenue
767 228 468 458 -33 195 195 436 312 400
Operating Cost of Revenue
767 228 468 458 -33 195 195 436 312 400
Total Operating Expenses
-30 481 209 183 667 397 375 184 301 147
Selling, General & Admin Expense
-123 370 133 116 575 329 328 107 219 86
Depreciation Expense
34 50 35 34 31 29 24 34 30 30
Other Operating Expenses / (Income)
34 33 28 20 38 23 10 29 41 21
Restructuring Charge
34 29 19 17 24 13 12 13 20 13
Other Special Charges / (Income)
-9.30 -1.70 -6.00 -3.80 -1.80 2.40 0.30 2.20 -8.10 -2.40
Total Other Income / (Expense), net
-53 -50 -52 -47 -49 -50 -48 -47 -61 -61
Interest & Investment Income
-53 -50 -52 -47 -49 -50 -48 -47 -61 -61
Income Tax Expense
121 4.50 4.90 4.40 6.00 3.10 -7.80 -1.60 9.90 7.80
Net Income / (Loss) Attributable to Noncontrolling Interest
62 38 44 37 48 35 39 26 47 31
Basic Earnings per Share
($0.86) ($0.25) ($0.12) ($0.10) - ($0.04) $0.15 ($0.20) ($0.24) ($0.28)
Weighted Average Basic Shares Outstanding
126.12M 126.17M 126.13M 125.97M 125.61M 125.75M 125.72M 125.21M 91.95M 88.91M
Diluted Earnings per Share
($0.86) ($0.25) ($0.12) ($0.10) - ($0.04) $0.15 ($0.20) ($0.24) ($0.28)
Weighted Average Diluted Shares Outstanding
126.12M 126.17M 126.13M 125.97M 125.61M 125.75M 127.37M 125.21M 91.95M 88.91M
Weighted Average Basic & Diluted Shares Outstanding
127.61M 127.11M 127.12M 127.09M 126.61M 126.49M 126.50M 126.48M 126.03M 89.95M

Annual Cash Flow Statements for Surgery Partners

This table details how cash moves in and out of Surgery Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
74 -87 -107 72 225 -92 9.40 12 -17
Net Cash From Operating Activities
300 294 159 87 247 130 145 125 84
Net Cash From Continuing Operating Activities
300 294 159 87 247 130 145 125 84
Net Income / (Loss) Continuing Operations
13 135 87 71 1.30 45 -96 85 73
Consolidated Net Income / (Loss)
13 135 87 71 1.30 45 -96 85 73
Depreciation Expense
153 118 115 99 95 77 67 40 35
Non-Cash Adjustments To Reconcile Net Income
122 106 96 -16 93 68 114 37 165
Changes in Operating Assets and Liabilities, net
13 -65 -139 -67 58 -60 59 -37 -194
Net Cash From Investing Activities
-489 -226 -308 -332 -88 -85 -129 -185 -135
Net Cash From Continuing Investing Activities
-489 -226 -308 -332 -88 -85 -129 -185 -135
Purchase of Property, Plant & Equipment
-90 -89 -81 -58 -43 -74 -40 -39 -33
Acquisitions
-381 -130 -242 -286 -105 -14 -107 -146 -113
Sale of Property, Plant & Equipment
2.60 26 13 6.00 59 18 19 - -
Divestitures
4.60 1.40 13 5.40 0.00 - - 0.77 11
Other Investing Activities, net
-25 -34 -12 0.30 0.60 -0.20 -1.50 0.00 -
Net Cash From Financing Activities
262 -155 42 316 67 -136 -6.30 71 33
Net Cash From Continuing Financing Activities
262 -155 42 316 67 -136 -6.30 71 33
Repayment of Debt
-1,307 -844 -883 -373 -226 -518 -168 -493 -336
Repurchase of Common Equity
0.00 0.00 -25 -28 0.00 0.00 -2.00 0.00 0.00
Payment of Dividends
-161 -138 -150 -165 -137 -124 -119 -86 -82
Issuance of Debt
1,730 827 218 299 429 507 283 651 196
Issuance of Common Equity
0.00 0.00 883 582 0.00 0.00 - 0.00 251
Cash Interest Paid
200 170 219 194 204 180 145 79 97
Cash Income Taxes Paid
1.60 1.40 1.80 1.50 1.70 1.60 2.20 0.66 1.09

Quarterly Cash Flow Statements for Surgery Partners

This table details how cash moves in and out of Surgery Partners' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
48 8.30 28 -11 -40 59 -68 -37 128 -73
Net Cash From Operating Activities
111 65 83 41 63 105 52 75 7.20 30
Net Cash From Continuing Operating Activities
111 65 83 41 63 105 52 75 7.20 30
Net Income / (Loss) Continuing Operations
-47 6.40 28 24 47 30 58 1.20 23 5.60
Consolidated Net Income / (Loss)
-47 6.40 28 24 47 30 58 1.20 23 5.60
Depreciation Expense
34 50 35 34 31 29 24 34 30 30
Non-Cash Adjustments To Reconcile Net Income
34 34 36 18 41 24 11 30 34 64
Changes in Operating Assets and Liabilities, net
90 -26 -16 -35 -57 23 -41 9.60 -80 -69
Net Cash From Investing Activities
-112 -50 -244 -83 -58 -26 -71 -71 -72 -54
Net Cash From Continuing Investing Activities
-112 -50 -244 -83 -58 -26 -71 -71 -72 -54
Purchase of Property, Plant & Equipment
-22 -20 -27 -21 -20 -19 -26 -24 -23 -17
Acquisitions
-88 -27 -210 -57 -31 -7.10 -42 -50 -64 -37
Sale of Property, Plant & Equipment
1.10 - - 1.50 - -0.30 18 8.00 13 -
Divestitures
0.60 - - - 0.40 1.00 - - 1.30 -
Other Investing Activities, net
-3.50 -2.80 -12 -7.00 -7.40 -0.30 -22 -4.10 0.10 -
Net Cash From Financing Activities
48 -7.30 190 32 -45 -20 -49 -41 193 -48
Net Cash From Continuing Financing Activities
48 -7.30 190 32 -45 -20 -49 -41 193 -48
Repayment of Debt
-174 -139 -873 -122 -724 -79 -20 -20 -795 -52
Payment of Dividends
-44 -37 -41 -39 -28 -34 -40 -37 -36 -35
Issuance of Debt
266 168 1,103 193 707 93 11 16 167 39

Annual Balance Sheets for Surgery Partners

This table presents Surgery Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
7,890 6,877 6,682 6,118 5,413 5,019 4,676 4,623 2,305 2,104
Total Current Assets
1,119 895 921 946 802 526 588 563 362 311
Cash & Equivalents
270 196 283 390 318 93 184 175 70 58
Accounts Receivable
579 496 456 430 382 327 308 288 221 178
Inventories, net
88 75 71 61 56 46 43 45 29 26
Prepaid Expenses
36 31 31 26 18 18 16 17 43 35
Other Current Assets
146 97 79 39 27 42 37 39 - 15
Plant, Property, & Equipment, net
1,088 969 877 0.00 0.00 523 426 0.00 0.00 185
Total Noncurrent Assets
5,682 5,013 4,885 5,172 4,612 3,970 3,662 4,060 1,943 1,609
Long-Term Investments
215 184 190 89 90 93 79 74 35 34
Goodwill
5,068 4,326 4,137 3,912 3,468 3,402 3,383 3,347 1,555 1,408
Intangible Assets
46 55 42 44 47 47 54 59 48 54
Noncurrent Deferred & Refundable Income Taxes
0.00 90 92 114 125 99 109 132 84 94
Other Noncurrent Operating Assets
353 359 423 1,013 882 329 37 49 16 19
Total Liabilities & Shareholders' Equity
7,890 6,877 6,682 6,118 5,413 5,019 4,676 4,623 2,305 2,104
Total Liabilities
4,255 3,515 3,399 3,818 3,790 3,320 2,892 2,656 1,800 1,623
Total Current Liabilities
624 523 493 537 557 398 349 303 187 181
Short-Term Debt
101 73 63 60 64 56 56 59 28 27
Accounts Payable
209 172 152 125 100 97 83 85 50 45
Current Employee Benefit Liabilities
60 74 69 77 65 54 55 50 29 26
Other Current Liabilities
254 204 210 210 217 191 155 110 80 82
Total Noncurrent Liabilities
3,630 2,992 2,906 3,281 3,233 2,921 2,542 2,353 1,613 1,442
Long-Term Debt
3,269 2,702 2,559 2,878 2,792 2,525 2,271 2,131 1,414 1,228
Noncurrent Deferred & Payable Income Tax Liabilities
39 0.00 - - - - - - 122 120
Other Noncurrent Operating Liabilities
322 290 347 403 441 397 271 222 76 94
Redeemable Noncontrolling Interest
439 327 342 330 741 716 686 630 181 183
Total Equity & Noncontrolling Interests
3,196 3,035 2,941 1,970 882 983 1,099 1,337 325 298
Total Preferred & Common Equity
1,790 1,987 1,998 1,089 116 297 405 655 9.68 -4.03
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,790 1,987 1,998 1,089 116 297 405 655 9.68 -4.03
Common Stock
2,522 2,499 2,479 1,623 608 663 674 696 321 317
Retained Earnings
-737 -569 -557 -503 -432 -316 -247 -41 -311 -321
Accumulated Other Comprehensive Income / (Loss)
4.80 58 76 -32 -61 -51 -22 0.00 - -
Noncontrolling Interest
1,407 1,047 943 881 767 687 694 682 315 302

Quarterly Balance Sheets for Surgery Partners

This table presents Surgery Partners' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
7,534 7,489 6,976 6,780 6,621 6,643 6,537
Total Current Assets
1,036 1,013 896 876 810 869 738
Cash & Equivalents
222 214 185 236 177 246 155
Accounts Receivable
543 523 494 463 450 453 422
Inventories, net
82 81 77 69 70 72 69
Prepaid Expenses
45 45 32 35 39 29 36
Other Current Assets
144 150 108 73 73 69 57
Plant, Property, & Equipment, net
1,005 1,006 983 940 0.00 0.00 0.00
Total Noncurrent Assets
5,494 5,470 5,097 4,964 5,810 5,774 5,798
Long-Term Investments
215 227 189 196 192 192 189
Goodwill
4,862 4,859 4,451 4,301 4,291 4,253 4,187
Noncurrent Deferred & Refundable Income Taxes
79 82 87 105 106 93 103
Other Noncurrent Operating Assets
339 303 370 362 1,221 1,237 1,320
Total Liabilities & Shareholders' Equity
7,534 7,489 6,976 6,780 6,621 6,643 6,537
Total Liabilities
3,986 3,870 3,614 3,461 3,310 3,355 4,092
Total Current Liabilities
575 552 523 501 459 475 624
Short-Term Debt
97 92 77 62 65 63 117
Accounts Payable
171 174 174 149 132 144 138
Current Employee Benefit Liabilities
65 63 69 82 64 68 69
Other Current Liabilities
242 222 204 208 198 200 292
Total Noncurrent Liabilities
3,411 3,318 3,091 2,960 2,851 2,880 3,468
Long-Term Debt
3,094 3,040 2,794 2,640 2,505 2,531 3,103
Other Noncurrent Operating Liabilities
317 279 297 320 346 349 365
Redeemable Noncontrolling Interest
436 442 324 332 328 346 339
Total Equity & Noncontrolling Interests
3,112 3,176 3,038 2,987 2,983 2,943 2,105
Total Preferred & Common Equity
1,897 1,952 1,967 2,005 2,018 1,962 1,173
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,897 1,952 1,967 2,005 2,018 1,962 1,173
Common Stock
2,515 2,512 2,497 2,496 2,503 2,479 1,624
Retained Earnings
-629 -597 -582 -568 -563 -582 -534
Accumulated Other Comprehensive Income / (Loss)
11 37 52 77 79 65 83
Noncontrolling Interest
1,215 1,224 1,071 982 965 981 933

Annual Metrics And Ratios for Surgery Partners

This table displays calculated financial ratios and metrics derived from Surgery Partners' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - -
Revenue Growth
13.52% 8.03% 14.12% 19.62% 1.57% 3.38% 0.00% 19.33% 138.02%
EBITDA Growth
12.40% -3.02% 14.71% 44.35% -10.39% 113.50% 0.00% 256.18% -6.21%
EBIT Growth
6.34% -4.98% 14.23% 65.14% -21.63% 200.13% 0.00% 675.87% -51.10%
NOPAT Growth
-90.98% 20.73% 3.48% 105.40% -34.26% 257.79% 0.00% 78.98% 184.91%
Net Income Growth
-90.76% 55.52% 23.06% 5,338.46% -97.12% 147.18% 0.00% 16.80% 369.28%
EPS Growth
-1,377.78% 84.75% 47.32% 64.89% -39.30% 53.83% 0.00% 400.00% 101.96%
Operating Cash Flow Growth
2.14% 85.01% 82.32% -64.72% 90.66% -10.44% 0.00% 48.25% 284.90%
Free Cash Flow Firm Growth
-22,831.05% 100.81% 6.04% -382.69% 395.61% 0.00% 0.00% 77.38% 94.85%
Invested Capital Growth
13.26% 5.99% 14.11% 16.90% -0.54% 6.38% 0.00% 12.05% 11.93%
Revenue Q/Q Growth
4.32% 1.04% 3.97% 2.86% 1.70% 1.44% 0.00% 3.87% 0.00%
EBITDA Q/Q Growth
6.03% 1.99% -2.89% 4.07% 12.02% 68.39% 0.00% 20.14% 0.00%
EBIT Q/Q Growth
7.95% 2.24% -5.63% 6.52% 15.46% 112.66% 0.00% 29.18% 0.00%
NOPAT Q/Q Growth
-89.11% 5.77% -7.97% -15.71% 15.46% 148.10% 0.00% 73.64% 0.00%
Net Income Q/Q Growth
-88.19% 20.91% -18.39% -6.61% 105.42% 153.37% 0.00% 2.41% 0.00%
EPS Q/Q Growth
-182.98% 72.73% -156.52% 17.04% 13.08% 53.74% 0.00% -44.44% 0.00%
Operating Cash Flow Q/Q Growth
19.42% 23.24% -7.30% 14.15% -6.26% -13.44% 0.00% 6.99% 59.38%
Free Cash Flow Firm Q/Q Growth
-65.93% -92.29% 45.23% -146.10% -41.60% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
3.45% 3.01% 2.10% 10.82% 6.87% 3.48% 0.00% 2.53% 0.00%
Profitability Metrics
- - - - - - - - -
Gross Margin
38.28% 71.06% 42.66% 42.44% 41.47% 42.24% 28.04% 28.31% 30.27%
EBITDA Margin
16.10% 16.26% 18.12% 18.02% 14.93% 16.93% 8.20% 20.28% 6.79%
Operating Margin
11.20% 11.96% 13.59% 13.58% 9.84% 12.88% 4.39% 17.15% 15.08%
EBIT Margin
11.20% 11.96% 13.59% 13.58% 9.84% 12.75% 4.39% 16.83% 2.59%
Profit (Net Income) Margin
0.40% 4.93% 3.43% 3.18% 0.07% 2.46% -5.40% 7.43% 7.59%
Tax Burden Percent
8.50% 100.22% 78.88% 87.07% -6.91% 82.60% 138.15% 92.30% -95.68%
Interest Burden Percent
42.17% 41.16% 31.95% 26.87% -10.27% 23.38% -88.95% 47.82% -306.47%
Effective Tax Rate
91.50% -0.22% 21.12% 12.93% 0.00% 17.40% 0.00% 7.70% 0.00%
Return on Invested Capital (ROIC)
0.48% 5.88% 5.34% 5.96% 3.14% 4.91% 1.42% 10.40% 6.51%
ROIC Less NNEP Spread (ROIC-NNEP)
-0.17% -2.64% -2.70% -1.88% -2.10% -1.81% -5.86% 2.70% 4.15%
Return on Net Nonoperating Assets (RNNOA)
-0.13% -1.80% -2.23% -2.35% -3.06% -2.32% -6.77% 6.85% 14.20%
Return on Equity (ROE)
0.36% 4.07% 3.12% 3.60% 0.08% 2.59% -5.36% 17.25% 20.71%
Cash Return on Invested Capital (CROIC)
-11.96% 0.06% -7.83% -9.62% 3.68% -1.28% 0.00% -0.96% -4.75%
Operating Return on Assets (OROA)
4.72% 4.84% 5.39% 5.24% 3.51% 4.82% 1.67% 8.74% 1.25%
Return on Assets (ROA)
0.17% 2.00% 1.36% 1.23% 0.02% 0.93% -2.06% 3.86% 3.68%
Return on Common Equity (ROCE)
0.19% 2.44% 1.72% 1.11% 0.01% 0.52% -1.51% 0.10% -7.89%
Return on Equity Simple (ROE_SIMPLE)
0.70% 6.81% 4.35% 6.49% 1.12% 15.20% -23.63% 879.23% -1,808.47%
Net Operating Profit after Tax (NOPAT)
30 329 272 263 128 195 54 181 101
NOPAT Margin
0.95% 11.98% 10.72% 11.83% 6.89% 10.64% 3.07% 15.83% 10.56%
Net Nonoperating Expense Percent (NNEP)
0.65% 8.51% 8.04% 7.84% 5.24% 6.72% 7.27% 7.70% 2.36%
Return On Investment Capital (ROIC_SIMPLE)
0.45% 5.66% 4.89% - - - - - -
Cost of Revenue to Revenue
61.72% 28.94% 57.34% 57.56% 58.53% 57.76% 71.96% 71.69% 69.73%
SG&A Expenses to Revenue
15.92% 48.77% 20.80% 20.96% 21.57% 19.26% 5.28% 5.26% 5.83%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
27.08% 59.11% 29.06% 28.86% 31.63% 29.35% 23.65% 11.15% 15.19%
Earnings before Interest and Taxes (EBIT)
349 328 345 302 183 234 78 193 25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
501 446 460 401 278 310 145 232 65
Valuation Ratios
- - - - - - - - -
Price to Book Value (P/BV)
1.50 2.04 1.25 4.04 12.67 2.61 1.18 79.43 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.86 1.48 0.99 1.98 0.79 0.42 0.27 0.67 1.03
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 81.31 690.51
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.23% 0.14%
Enterprise Value to Invested Capital (EV/IC)
1.14 1.36 1.09 1.70 1.33 1.12 1.02 1.41 1.60
Enterprise Value to Revenue (EV/Rev)
2.38 2.85 2.34 3.63 2.91 2.50 2.21 2.27 2.75
Enterprise Value to EBITDA (EV/EBITDA)
14.80 17.52 12.91 20.13 19.52 14.75 27.01 11.20 40.40
Enterprise Value to EBIT (EV/EBIT)
21.28 23.83 17.21 26.72 29.62 19.58 50.42 13.50 106.07
Enterprise Value to NOPAT (EV/NOPAT)
250.40 23.78 21.81 30.69 42.32 23.47 72.03 14.34 26.01
Enterprise Value to Operating Cash Flow (EV/OCF)
24.73 26.60 37.40 92.70 21.96 35.31 27.13 20.77 31.19
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 2,420.75 0.00 0.00 36.07 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - -
Debt to Equity
0.93 0.83 0.80 1.28 1.76 1.52 1.30 2.85 2.61
Long-Term Debt to Equity
0.90 0.80 0.78 1.25 1.72 1.49 1.27 2.80 2.55
Financial Leverage
0.75 0.68 0.83 1.25 1.46 1.28 1.16 2.53 3.43
Leverage Ratio
2.11 2.04 2.29 2.94 3.14 2.78 2.48 4.47 5.63
Compound Leverage Factor
0.89 0.84 0.73 0.79 -0.32 0.65 -2.20 2.14 -17.27
Debt to Total Capital
48.11% 45.22% 44.40% 56.10% 63.77% 60.30% 56.59% 74.06% 72.28%
Short-Term Debt to Total Capital
1.45% 1.19% 1.06% 1.15% 1.44% 1.31% 1.35% 1.43% 1.57%
Long-Term Debt to Total Capital
46.66% 44.02% 43.34% 54.95% 62.33% 58.99% 55.24% 72.63% 70.71%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
26.34% 22.40% 21.76% 23.11% 33.65% 32.77% 33.57% 25.44% 27.95%
Common Equity to Total Capital
25.55% 32.38% 33.84% 20.79% 2.58% 6.93% 9.84% 0.50% -0.23%
Debt to EBITDA
6.72 6.22 5.70 7.33 10.28 8.32 16.02 6.21 19.25
Net Debt to EBITDA
5.75 5.37 4.67 6.14 8.81 7.73 14.21 5.76 17.83
Long-Term Debt to EBITDA
6.52 6.06 5.56 7.18 10.05 8.14 15.64 6.09 18.83
Debt to NOPAT
113.71 8.44 9.63 11.17 22.30 13.24 42.72 7.95 12.39
Net Debt to NOPAT
97.35 7.29 7.89 9.35 19.11 12.29 37.89 7.37 11.48
Long-Term Debt to NOPAT
110.29 8.22 9.40 10.94 21.80 12.96 41.70 7.80 12.12
Altman Z-Score
0.86 1.20 0.95 1.18 0.63 0.60 0.52 0.93 0.72
Noncontrolling Interest Sharing Ratio
46.02% 40.02% 44.70% 69.30% 87.59% 79.87% 71.76% 99.43% 138.11%
Liquidity Ratios
- - - - - - - - -
Current Ratio
1.79 1.71 1.87 1.76 1.44 1.32 1.68 1.94 1.72
Quick Ratio
1.36 1.32 1.50 1.53 1.26 1.05 1.41 1.55 1.30
Cash Flow Metrics
- - - - - - - - -
Free Cash Flow to Firm (FCFF)
-734 3.23 -399 -425 150 -51 0.00 -17 -74
Operating Cash Flow to CapEx
341.80% 466.35% 234.56% 168.80% 0.00% 231.25% 701.94% 320.23% 252.64%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - -
Asset Turnover
0.42 0.40 0.40 0.39 0.36 0.38 0.38 0.52 0.48
Accounts Receivable Turnover
5.79 5.76 5.73 5.48 5.25 5.77 5.95 5.75 5.95
Inventory Turnover
23.50 10.83 21.98 21.80 21.20 23.59 28.86 30.21 27.16
Fixed Asset Turnover
3.03 2.97 0.00 0.00 0.00 3.86 0.00 0.00 5.34
Accounts Payable Turnover
10.10 4.91 10.53 11.38 11.06 11.75 15.17 17.27 15.14
Days Sales Outstanding (DSO)
63.03 63.38 63.71 66.63 69.57 63.23 61.36 63.47 61.36
Days Inventory Outstanding (DIO)
15.53 33.70 16.61 16.74 17.22 15.47 12.65 12.08 13.44
Days Payable Outstanding (DPO)
36.13 74.35 34.66 32.08 33.01 31.05 24.05 21.14 24.10
Cash Conversion Cycle (CCC)
42.43 22.73 45.66 51.30 53.78 47.65 49.96 54.41 50.69
Capital & Investment Metrics
- - - - - - - - -
Invested Capital
6,521 5,757 5,432 4,760 4,072 4,094 3,849 1,842 1,644
Invested Capital Turnover
0.51 0.49 0.50 0.50 0.46 0.46 0.46 0.66 0.62
Increase / (Decrease) in Invested Capital
764 326 672 688 -22 246 0.00 198 175
Enterprise Value (EV)
7,422 7,816 5,939 8,074 5,421 4,572 3,923 2,601 2,635
Market Capitalization
2,691 4,047 2,506 4,403 1,465 775 479 769 987
Book Value per Share
$14.08 $15.71 $22.21 $13.21 $2.29 $6.00 $8.28 $0.20 ($0.08)
Tangible Book Value per Share
($26.15) ($18.92) ($24.25) ($34.77) ($67.32) ($63.69) ($62.03) ($32.86) ($30.43)
Total Capital
7,006 6,137 5,905 5,239 4,480 4,280 4,111 1,947 1,737
Total Debt
3,370 2,775 2,622 2,939 2,857 2,581 2,327 1,442 1,255
Total Long-Term Debt
3,269 2,702 2,559 2,878 2,792 2,525 2,271 1,414 1,228
Net Debt
2,885 2,395 2,149 2,460 2,449 2,395 2,064 1,337 1,163
Capital Expenditures (CapEx)
88 63 68 52 -16 56 21 39 33
Debt-free, Cash-free Net Working Capital (DFCFNWC)
327 249 208 80 -8.80 91 110 133 99
Debt-free Net Working Capital (DFNWC)
596 445 490 470 309 183 295 203 157
Net Working Capital (NWC)
495 372 428 409 245 127 239 175 130
Net Nonoperating Expense (NNE)
17 193 185 192 127 150 150 96 28
Net Nonoperating Obligations (NNO)
2,885 2,395 2,149 2,460 2,449 2,395 2,064 1,337 1,163
Total Depreciation and Amortization (D&A)
153 118 115 99 95 77 67 40 40
Debt-free, Cash-free Net Working Capital to Revenue
10.50% 9.09% 8.17% 3.59% -0.47% 4.95% 6.23% 11.64% 10.31%
Debt-free Net Working Capital to Revenue
19.15% 16.23% 19.31% 21.11% 16.62% 10.01% 16.63% 17.73% 16.35%
Net Working Capital to Revenue
15.89% 13.56% 16.84% 18.39% 13.16% 6.96% 13.49% 15.30% 13.51%
Earnings Adjustments
- - - - - - - - -
Adjusted Basic Earnings per Share
($1.33) ($0.09) ($0.59) ($1.12) ($3.19) ($2.29) ($4.96) $0.20 $0.04
Adjusted Weighted Average Basic Shares Outstanding
126.12M 125.61M 91.95M 72.43M 59.86M 49.29M 48.03M 48.02M 36.07M
Adjusted Diluted Earnings per Share
($1.33) ($0.09) ($0.59) ($1.12) ($3.19) ($2.29) ($4.96) $0.20 $0.04
Adjusted Weighted Average Diluted Shares Outstanding
126.12M 125.61M 91.95M 72.43M 59.86M 49.29M 48.03M 48.19M 37.46M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 ($3.19) ($2.29) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
127.61M 126.61M 126.03M 89.36M 48.78M 48.28M 48.80M 48.63M 48.16M
Normalized Net Operating Profit after Tax (NOPAT)
300 275 272 284 167 216 158 176 112
Normalized NOPAT Margin
9.62% 10.02% 10.70% 12.78% 9.00% 11.80% 8.94% 15.37% 11.67%
Pre Tax Income Margin
4.72% 4.92% 4.34% 3.65% -1.01% 2.98% -3.91% 8.05% -7.93%
Debt Service Ratios
- - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - -
Dividend Payout Ratio
1,287.20% 101.92% 172.64% 232.67% 10,538.46% 275.83% -124.48% 100.93% 112.42%
Augmented Payout Ratio
1,287.20% 101.92% 201.61% 271.71% 10,538.46% 275.83% -126.57% 100.93% 112.42%

Quarterly Metrics And Ratios for Surgery Partners

This table displays calculated financial ratios and metrics derived from Surgery Partners' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
17.54% 14.29% 14.16% 7.69% 4.00% 8.62% 8.48% 11.74% 15.88% 10.98%
EBITDA Growth
21.51% -0.36% -1.97% 36.95% 7.03% 7.31% 16.75% -37.32% -9.96% 17.00%
EBIT Growth
25.35% -26.27% -13.11% 63.79% 7.64% 11.47% 27.58% -53.78% -17.94% 16.51%
NOPAT Growth
-188.83% -52.19% -35.92% 98.12% 35.92% 141.52% 88.99% -66.67% -26.57% -44.18%
Net Income Growth
-199.79% -78.45% -50.78% 1,925.00% 100.43% 430.36% 277.12% -97.20% -45.69% -31.71%
EPS Growth
0.00% -525.00% -180.00% 50.00% 0.00% 85.71% 171.43% -242.86% -300.00% 0.00%
Operating Cash Flow Growth
77.96% -37.67% 58.93% -45.37% 769.44% 252.19% 23.75% -6.64% -63.45% 99.33%
Free Cash Flow Firm Growth
-257.92% -249.67% -130.69% 20.35% 61.08% 80.47% 64.30% 45.50% -1.24% -131.47%
Invested Capital Growth
13.26% 12.78% 14.50% 7.60% 5.99% 5.05% 8.42% 9.47% 14.11% 23.86%
Revenue Q/Q Growth
12.20% 1.09% 6.23% -2.45% 9.09% 0.97% 0.21% -5.78% 13.94% 0.85%
EBITDA Q/Q Growth
44.91% -7.11% 9.02% -17.21% 18.83% -8.61% 52.31% -35.30% 19.15% -0.57%
EBIT Q/Q Growth
108.70% -28.18% 11.58% -25.05% 22.76% -15.37% 110.34% -50.74% 27.13% -3.14%
NOPAT Q/Q Growth
-323.23% -50.56% 12.39% -28.39% 20.14% -33.73% 247.46% -50.87% 113.49% -48.14%
Net Income Q/Q Growth
-828.13% -77.46% 16.87% -47.97% 57.24% -48.53% 4,708.33% -94.85% 316.07% -63.40%
EPS Q/Q Growth
-244.00% -108.33% -20.00% 0.00% 0.00% -126.67% 175.00% 16.67% 14.29% -33.33%
Operating Cash Flow Q/Q Growth
70.86% -21.26% 103.44% -34.98% -40.15% 100.77% -30.07% 934.72% -75.76% -29.45%
Free Cash Flow Firm Q/Q Growth
-24.26% 6.61% -108.04% -48.25% -21.40% 38.39% 28.17% 27.55% 39.08% -12.62%
Invested Capital Q/Q Growth
3.45% -0.11% 7.70% 1.77% 3.01% 1.41% 1.21% 0.25% 2.10% 4.66%
Profitability Metrics
- - - - - - - - - -
Gross Margin
11.23% 70.35% 38.55% 36.14% 104.43% 71.07% 70.76% 34.52% 55.88% 35.59%
EBITDA Margin
18.63% 14.42% 15.69% 15.29% 18.02% 16.54% 18.27% 12.02% 17.51% 16.74%
Operating Margin
14.70% 7.91% 11.13% 10.59% 13.79% 12.25% 14.62% 6.96% 13.32% 11.94%
EBIT Margin
14.70% 7.91% 11.13% 10.59% 13.79% 12.25% 14.62% 6.96% 13.32% 11.94%
Profit (Net Income) Margin
-5.39% 0.83% 3.73% 3.39% 6.35% 4.41% 8.64% 0.18% 3.30% 0.90%
Tax Burden Percent
-62.80% 58.72% 85.29% 84.67% 88.61% 90.55% 115.63% -300.00% 70.18% 41.79%
Interest Burden Percent
58.38% 17.90% 39.27% 37.76% 51.97% 39.71% 51.13% -0.86% 35.24% 18.08%
Effective Tax Rate
162.80% 41.28% 14.71% 15.33% 11.39% 9.45% -15.63% 0.00% 29.82% 58.21%
Return on Invested Capital (ROIC)
-4.68% 2.33% 4.64% 4.44% 5.99% 5.52% 8.49% 2.44% 4.66% 2.54%
ROIC Less NNEP Spread (ROIC-NNEP)
-3.43% 1.16% 2.84% 2.71% 4.09% 3.77% 6.24% 1.13% 2.80% 1.58%
Return on Net Nonoperating Assets (RNNOA)
-2.59% 0.85% 2.01% 1.90% 2.80% 3.37% 5.37% 0.96% 2.31% 1.95%
Return on Equity (ROE)
-7.27% 3.18% 6.65% 6.33% 8.79% 8.89% 13.87% 3.40% 6.97% 4.48%
Cash Return on Invested Capital (CROIC)
-11.96% -7.44% -8.41% -1.21% 0.06% 0.77% -2.69% -5.19% -7.83% -15.16%
Operating Return on Assets (OROA)
6.20% 3.30% 4.56% 4.35% 5.58% 5.00% 6.03% 2.81% 5.29% 4.79%
Return on Assets (ROA)
-2.27% 0.35% 1.53% 1.39% 2.57% 1.80% 3.56% 0.07% 1.31% 0.36%
Return on Common Equity (ROCE)
-3.92% 1.81% 3.81% 3.74% 5.27% 4.90% 7.73% 1.88% 3.86% 2.01%
Return on Equity Simple (ROE_SIMPLE)
0.00% 5.58% 6.61% 8.05% 0.00% 5.58% 4.35% 2.31% 0.00% 9.09%
Net Operating Profit after Tax (NOPAT)
-80 36 72 64 90 75 113 32 66 31
NOPAT Margin
-9.23% 4.64% 9.49% 8.97% 12.22% 11.10% 16.90% 4.88% 9.35% 4.99%
Net Nonoperating Expense Percent (NNEP)
-1.26% 1.17% 1.80% 1.72% 1.90% 1.75% 2.25% 1.31% 1.86% 0.96%
Return On Investment Capital (ROIC_SIMPLE)
-1.22% - - - 1.55% - - - 1.19% -
Cost of Revenue to Revenue
88.77% 29.65% 61.45% 63.86% -4.43% 28.93% 29.24% 65.48% 44.12% 64.41%
SG&A Expenses to Revenue
-14.17% 48.00% 17.41% 16.14% 78.15% 48.81% 49.09% 16.00% 30.96% 13.86%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
-3.47% 62.45% 27.42% 25.55% 90.64% 58.82% 56.14% 27.56% 42.55% 23.65%
Earnings before Interest and Taxes (EBIT)
127 61 85 76 101 83 98 46 94 74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
161 111 120 110 133 112 122 80 124 104
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.50 2.16 1.55 1.92 2.04 1.85 2.82 2.21 1.25 1.79
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.86 1.37 1.05 1.35 1.48 1.36 2.14 1.66 0.99 0.86
Price to Earnings (P/E)
0.00 0.00 0.00 6,288.82 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.14 1.35 1.17 1.31 1.36 1.30 1.67 1.44 1.09 1.18
Enterprise Value to Revenue (EV/Rev)
2.38 2.85 2.55 2.74 2.85 2.68 3.45 3.00 2.34 2.56
Enterprise Value to EBITDA (EV/EBITDA)
14.80 17.99 15.59 16.11 17.52 16.65 21.37 18.98 12.91 13.20
Enterprise Value to EBIT (EV/EBIT)
21.28 26.32 21.41 21.43 23.83 22.71 29.40 26.88 17.21 17.09
Enterprise Value to NOPAT (EV/NOPAT)
250.40 31.25 24.46 22.21 23.78 23.44 32.18 38.96 21.81 21.13
Enterprise Value to Operating Cash Flow (EV/OCF)
24.73 33.84 25.39 29.48 26.60 30.55 56.16 50.99 37.40 36.49
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 2,420.75 173.84 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.93 0.90 0.87 0.85 0.83 0.81 0.78 0.79 0.80 1.32
Long-Term Debt to Equity
0.90 0.87 0.84 0.83 0.80 0.80 0.76 0.77 0.78 1.27
Financial Leverage
0.75 0.73 0.71 0.70 0.68 0.89 0.86 0.85 0.83 1.23
Leverage Ratio
2.11 2.08 2.04 2.05 2.04 2.31 2.27 2.29 2.29 2.83
Compound Leverage Factor
1.23 0.37 0.80 0.77 1.06 0.92 1.16 -0.02 0.81 0.51
Debt to Total Capital
48.11% 47.35% 46.40% 46.06% 45.22% 44.88% 43.70% 44.10% 44.40% 56.84%
Short-Term Debt to Total Capital
1.45% 1.44% 1.37% 1.24% 1.19% 1.03% 1.10% 1.07% 1.06% 2.06%
Long-Term Debt to Total Capital
46.66% 45.91% 45.03% 44.83% 44.02% 43.85% 42.60% 43.03% 43.34% 54.78%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
26.34% 24.51% 24.68% 22.37% 22.40% 21.83% 21.98% 22.55% 21.76% 22.45%
Common Equity to Total Capital
25.55% 28.14% 28.92% 31.56% 32.38% 33.29% 34.32% 33.36% 33.84% 20.71%
Debt to EBITDA
6.72 6.75 6.62 6.04 6.22 6.18 5.98 6.29 5.70 6.80
Net Debt to EBITDA
5.75 5.83 5.69 5.25 5.37 5.19 5.12 5.23 4.67 6.07
Long-Term Debt to EBITDA
6.52 6.54 6.42 5.87 6.06 6.04 5.83 6.14 5.56 6.55
Debt to NOPAT
113.71 11.73 10.38 8.32 8.44 8.69 9.01 12.91 9.63 10.88
Net Debt to NOPAT
97.35 10.12 8.92 7.23 7.29 7.30 7.71 10.73 7.89 9.72
Long-Term Debt to NOPAT
110.29 11.37 10.07 8.09 8.22 8.49 8.78 12.60 9.40 10.49
Altman Z-Score
0.77 1.00 0.85 1.01 1.09 1.03 1.43 1.14 0.83 0.63
Noncontrolling Interest Sharing Ratio
46.02% 43.19% 42.70% 40.91% 40.02% 44.86% 44.26% 44.65% 44.70% 55.20%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.79 1.80 1.83 1.71 1.71 1.75 1.77 1.83 1.87 1.18
Quick Ratio
1.36 1.33 1.34 1.30 1.32 1.39 1.37 1.47 1.50 0.92
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-843 -679 -727 -349 -236 -194 -315 -439 -605 -994
Operating Cash Flow to CapEx
525.47% 322.77% 307.81% 208.72% 316.16% 544.79% 676.62% 457.06% 73.47% 171.68%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.42 0.42 0.41 0.41 0.40 0.41 0.41 0.40 0.40 0.40
Accounts Receivable Turnover
5.79 5.94 5.94 5.90 5.76 6.13 6.18 6.03 5.73 5.99
Inventory Turnover
23.50 30.90 30.50 27.32 10.83 22.67 26.34 29.22 21.98 25.81
Fixed Asset Turnover
3.03 3.07 0.00 0.00 2.97 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
10.10 14.64 15.10 12.76 4.91 10.89 13.72 14.72 10.53 12.95
Days Sales Outstanding (DSO)
63.03 61.48 61.48 61.86 63.38 59.50 59.10 60.52 63.71 60.95
Days Inventory Outstanding (DIO)
15.53 11.81 11.97 13.36 33.70 16.10 13.86 12.49 16.61 14.14
Days Payable Outstanding (DPO)
36.13 24.93 24.18 28.59 74.35 33.51 26.61 24.79 34.66 28.18
Cash Conversion Cycle (CCC)
42.43 48.36 49.27 46.62 22.73 42.09 46.35 48.22 45.66 46.91
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
6,521 6,303 6,310 5,859 5,757 5,589 5,511 5,445 5,432 5,320
Invested Capital Turnover
0.51 0.50 0.49 0.49 0.49 0.50 0.50 0.50 0.50 0.51
Increase / (Decrease) in Invested Capital
764 715 799 414 326 269 428 471 672 1,025
Enterprise Value (EV)
7,422 8,505 7,381 7,665 7,816 7,284 9,183 7,827 5,939 6,251
Market Capitalization
2,691 4,098 3,024 3,773 4,047 3,700 5,690 4,344 2,506 2,104
Book Value per Share
$14.08 $14.92 $15.36 $15.62 $15.71 $15.85 $15.96 $15.57 $22.21 $13.04
Tangible Book Value per Share
($26.15) ($23.32) ($22.87) ($19.72) ($18.92) ($18.15) ($17.97) ($18.18) ($24.25) ($33.51)
Total Capital
7,006 6,740 6,751 6,233 6,137 6,021 5,880 5,882 5,905 5,664
Total Debt
3,370 3,192 3,132 2,871 2,775 2,702 2,570 2,594 2,622 3,220
Total Long-Term Debt
3,269 3,094 3,040 2,794 2,702 2,640 2,505 2,531 2,559 3,103
Net Debt
2,885 2,755 2,692 2,497 2,395 2,270 2,200 2,157 2,149 2,876
Capital Expenditures (CapEx)
21 20 27 20 20 19 7.70 16 9.80 17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
327 336 340 265 249 201 239 211 208 76
Debt-free Net Working Capital (DFNWC)
596 558 553 450 445 437 416 457 490 231
Net Working Capital (NWC)
495 461 461 373 372 375 352 394 428 114
Net Nonoperating Expense (NNE)
-33 29 44 40 43 45 55 31 43 25
Net Nonoperating Obligations (NNO)
2,885 2,755 2,692 2,497 2,395 2,270 2,200 2,157 2,149 2,876
Total Depreciation and Amortization (D&A)
34 50 35 34 31 29 24 34 30 30
Debt-free, Cash-free Net Working Capital to Revenue
10.50% 11.26% 11.75% 9.47% 9.09% 7.40% 8.98% 8.09% 8.17% 3.12%
Debt-free Net Working Capital to Revenue
19.15% 18.69% 19.15% 16.09% 16.23% 16.09% 15.64% 17.50% 19.31% 9.45%
Net Working Capital to Revenue
15.89% 15.43% 15.95% 13.33% 13.56% 13.80% 13.21% 15.09% 16.84% 4.67%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.86) ($0.25) ($0.12) ($0.10) $0.00 ($0.04) $0.15 ($0.20) ($0.24) ($0.28)
Adjusted Weighted Average Basic Shares Outstanding
126.12M 126.17M 126.13M 125.97M 125.61M 125.75M 125.72M 125.21M 91.95M 88.91M
Adjusted Diluted Earnings per Share
($0.86) ($0.25) ($0.12) ($0.10) $0.00 ($0.04) $0.15 ($0.20) ($0.24) ($0.28)
Adjusted Weighted Average Diluted Shares Outstanding
126.12M 126.17M 126.13M 125.97M 125.61M 125.75M 127.37M 125.21M 91.95M 88.91M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
127.61M 127.11M 127.12M 127.09M 126.61M 126.49M 126.50M 126.48M 126.03M 89.95M
Normalized Net Operating Profit after Tax (NOPAT)
106 52 84 76 110 89 77 43 74 59
Normalized NOPAT Margin
12.29% 6.75% 10.98% 10.57% 14.94% 13.14% 11.52% 6.42% 10.50% 9.50%
Pre Tax Income Margin
8.58% 1.41% 4.37% 4.00% 7.17% 4.87% 7.47% -0.06% 4.70% 2.16%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
1,287.20% 136.48% 109.45% 88.51% 101.92% 130.56% 167.77% 325.33% 172.64% 165.38%
Augmented Payout Ratio
1,287.20% 136.48% 109.45% 88.51% 101.92% 130.56% 167.77% 325.33% 201.61% 165.38%

Frequently Asked Questions About Surgery Partners' Financials

When does Surgery Partners's fiscal year end?

According to the most recent income statement we have on file, Surgery Partners' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Surgery Partners' net income changed over the last 8 years?

Surgery Partners' net income appears to be on an upward trend, with a most recent value of $12.50 million in 2024, falling from $72.85 million in 2015. The previous period was $135.30 million in 2023. View Surgery Partners' forecast to see where analysts expect Surgery Partners to go next.

What is Surgery Partners's operating income?
Surgery Partners's total operating income in 2024 was $348.80 million, based on the following breakdown:
  • Total Gross Profit: $1.19 billion
  • Total Operating Expenses: $843.40 million
How has Surgery Partners revenue changed over the last 8 years?

Over the last 8 years, Surgery Partners' total revenue changed from $959.89 million in 2015 to $3.11 billion in 2024, a change of 224.4%.

How much debt does Surgery Partners have?

Surgery Partners' total liabilities were at $4.25 billion at the end of 2024, a 21.1% increase from 2023, and a 162.1% increase since 2015.

How much cash does Surgery Partners have?

In the past 9 years, Surgery Partners' cash and equivalents has ranged from $57.93 million in 2015 to $389.90 million in 2021, and is currently $269.50 million as of their latest financial filing in 2024.

How has Surgery Partners' book value per share changed over the last 8 years?

Over the last 8 years, Surgery Partners' book value per share changed from -0.08 in 2015 to 14.08 in 2024, a change of -16,941.5%.



This page (NASDAQ:SGRY) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners